Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M684Revenue (TTM) $M457Net Margin (%)-7.4Altman Z-Score1.7
Enterprise Value $M1,037EPS (TTM) $-1.0Operating Margin %1.9Piotroski F-Score4
P/E(ttm)--Beneish M-Score-2.7Pre-tax Margin (%)-5.3Higher ROA y-yN
Price/Book2.210-y EBITDA Growth Rate %--Quick Ratio1.6Cash flow > EarningsY
Price/Sales1.25-y EBITDA Growth Rate %--Current Ratio2.5Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %40.6ROA % (ttm)-4.3Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-12.3Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M42.9ROIC % (ttm)-4.7Gross Margin Increase y-yY

Gurus Latest Trades with AMRI

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
AMRIKen Fisher 2015-12-31 Add$17.08 - $20.5
($19.03)
$ 15.96-16%Add 19.06%203,450
AMRIKen Fisher 2015-09-30 Buy 0.01%$17.23 - $22.2
($20.37)
$ 15.96-22%New holding170,876
AMRIJoel Greenblatt 2014-09-30 Sold Out -0.03%$18.7 - $22.89
($20.45)
$ 15.96-22%Sold Out0
AMRIJoel Greenblatt 2014-06-30 Reduce-0.03%$14.63 - $19.89
($16.89)
$ 15.96-6%Reduce -47.95%102,934
AMRIGeorge Soros 2014-06-30 Sold Out -0.01%$14.63 - $19.89
($16.89)
$ 15.96-6%Sold Out0
AMRIGeorge Soros 2014-03-31 Buy 0.01%$10.08 - $19.91
($13.57)
$ 15.9618%New holding48,700
AMRIJoel Greenblatt 2013-09-30 Buy 0.1%$10.81 - $13.72
($12.29)
$ 15.9630%New holding228,216
AMRIJohn Rogers 2013-03-31 Sold Out -0.04%$5.28 - $10.84
($7.56)
$ 15.96111%Sold Out0
AMRIJohn Rogers 2012-12-31 Reduce-0.01%$3.45 - $5.5
($4.25)
$ 15.96276%Reduce -27.34%372,844
AMRIJohn Rogers 2012-06-30 Buy 0.03%$2.32 - $3.22
($2.81)
$ 15.96468%New holding473,769
AMRIFirst Eagle Investment 2010-12-31 Sold Out $5.05 - $6.93
($5.91)
$ 15.96170%Sold Out0
AMRIFirst Eagle Investment 2010-06-30 Buy $5.1 - $8.86
($7.07)
$ 15.96126%New holding10,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

AMRI is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


AMRI: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Hagen Steven RSVP Manufacturing & Pharmaceut 2016-08-09Sell1,401$15.294.38view
OCONNOR KEVINDirector 2016-05-31Sell5,000$14.4110.76view
Marth William SPresident and CEO 2016-05-16Buy12,500$12.8624.11view
Svokos GeorgeCOO 2016-05-13Buy12,500$12.8224.49view
Hagen Steven RSVP Manufacturing & Pharmaceut 2016-05-13Sell2,361$12.7724.98view
D AMBRA THOMAS EChairman, Board of Directors 2015-11-09Sell50,000$19.6-18.57view
D AMBRA CONSTANCE M10% Owner 2015-11-09Sell50,000$19.6-18.57view
Hagen Steven RSVP Manufacturing & Pharmaceut 2015-08-17Sell1,000$20.45-21.96view
Hagen Steven RSVP Manufacturing & Pharmaceut 2015-08-07Sell5,000$21.06-24.22view
D AMBRA THOMAS E PHDDirector 2015-06-10Sell20,000$19.77-19.27view

Press Releases about AMRI :

Quarterly/Annual Reports about AMRI:

News about AMRI:

Articles On GuruFocus.com
Weekly CFO Buys Highlight: TSON, PRTS, FXCM, AMRI, MN Dec 05 2011 

More From Other Websites
ALBANY MOLECULAR RESEARCH INC Files SEC form 8-K/A, Completion of Acquisition or Disposition of... Sep 23 2016
Albany Molecular Research, Inc. – Value Analysis (NASDAQ:AMRI) : September 15, 2016 Sep 15 2016
Albany Molecular Research, Inc. breached its 50 day moving average in a Bearish Manner : AMRI-US :... Sep 14 2016
Lifshitz & Miller Law Firm Announces Investigation of Accuride Corporation, Albany Molecular... Sep 07 2016
AMRI CEO to Present at Morgan Stanley Global Healthcare Conference Aug 30 2016
ALBANY MOLECULAR RESEARCH INC Files SEC form 8-K, Costs Associated with Exit or Disposal Activities,... Aug 29 2016
ETF’s with exposure to Albany Molecular Research, Inc. : August 26, 2016 Aug 26 2016
Albany Molecular Research, Inc. breached its 50 day moving average in a Bearish Manner : AMRI-US :... Aug 25 2016
AMRI CEO to Present at Baird 2016 Global Healthcare Conference Aug 24 2016
AMRI Licenses CRISPR-Cas9 Gene Editing Technology Aug 23 2016
Update in Lawsuit for Investors in Albany Molecular Research, Inc. shares announced by Shareholders... Aug 23 2016
ALBANY MOLECULAR RESEARCH INC Financials Aug 16 2016
Ryan & Maniskas, LLP Announces Investigation of Albany Molecular Research Inc. Aug 10 2016
Albany Molecular Research, Inc. :AMRI-US: Earnings Analysis: Q2, 2016 By the Numbers : August 10,... Aug 10 2016
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Albany Molecular... Aug 09 2016
Robbins Arroyo LLP Is Investigating the Officers and Directors of Albany Molecular Research, Inc.... Aug 08 2016
ALBANY MOLECULAR RESEARCH INC Files SEC form 10-Q, Quarterly Report Aug 05 2016
Edited Transcript of AMRI earnings conference call or presentation 4-Aug-16 12:30pm GMT Aug 04 2016
ALBANY MOLECULAR RESEARCH INC Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 04 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)